INDV · NASDAQ · STOCK
Indivior Pharmaceuticals (INDV) Stock Analysis
$35.83
52W $23.55 – $42.81
58/100
$4.47B
12.6
1.11
Is INDV Bullish or Bearish?
Mixed.
Innellis AI committee rates Indivior Pharmaceuticals Inc (INDV) Watch with a composite score of 58/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +1.74 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -18.26 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — eps growing 237.5% yoy. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- P/E of 11.9 is inexpensive for the broad market — Value
- ROE of 159.1% shows genuine earnings power backing the valuation — Value
- EPS growing 237.5% YoY — Growth
- 4 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Price-to-book of 49.6x prices in significant intangible value — Value
- Debt-to-equity of 5.43 adds balance-sheet risk to the value case — Value
- High leverage (debt-to-equity 5.43) amplifies downside in a stress scenario — Risk
- Current ratio of 0.71 is tight -- limited short-term liquidity cushion — Risk
- No news coverage in the last 14 days -- limited independent confirmation either way — News
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
58/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 43%
of 192 Healthcare peers
Value Analyst
neutral
55
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ P/E of 11.9 is inexpensive for the broad market
− Price-to-book of 49.6x prices in significant intangible value
Growth Analyst
bullish
79
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 237.5% YoY
Technical Analyst
neutral
58
/ 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
Risk Analyst
bearish
32
/ 100 · Moderate confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 5.43) amplifies downside in a stress scenario
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
60
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
− No news coverage in the last 14 days -- limited independent confirmation either way
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 58.3 to 58.3.
- Bullish support removed: 1 signal(s) disappeared.
- New bullish signals: 1 appeared.
Analyst-level changes:
- Value Analyst: +1 bullish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
50.6
Neutral
MACD Histogram
0.074
Bullish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Lh Ll
Support
$32.42
Resistance
$37.57
Bollinger %B
0.56
Inside Bands
Price vs Moving Averages
EMA 9
$35.83
Above
EMA 21
$35.81
Above
EMA 50
$36.37
Below
EMA 200
$34.52
Above
Fundamental Analysis
Valuation
100
Growth
83
Profitability
75
Financial Health
51
Cash Flow
15
Valuation
P/E Ratio
12.6×
P/B Ratio
-21.59×
PEG Ratio
0.07
Dividend Yield
0.00%
52W High
$42.81
52W Low
$23.55
Quality & Growth
ROE
-21428.6%
ROA
1744.2%
Gross Margin
8385.9%
Operating Margin
3888.9%
Revenue Growth YoY
—
Debt / Equity
-2.45
AI Fundamental Assessment
P/E ratio of 12.6 (inexpensive relative to a 15-40x range); Price-to-book of -21.6x; PEG ratio of 0.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -214.3%; Return on assets of 17.4%; Net margin of 26.7%; Gross margin of 83.9%; Current ratio of 0.84 (tight short-term liquidity); Debt-to-equity of -2.45; Free cash flow per share is negative (-0.89); Most recent quarter beat estimates by 29.0%; 4 consecutive earnings beats; EPS growth accelerating (+17.1% -> +19.8% QoQ); Analyst estimates rising over recent quarters
Get the Full INDV Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →